Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Disitamab Vedotin · RC48, RC48-ADC

Antibody-drug conjugate · Kills target cells, directed at HER2 (ERBB2) (ERBB2) · developed by RemeGen Co.

Phase 1/2 Most advanced trial

What is Disitamab Vedotin?

Disitamab vedotin is an antibody-drug conjugate in which a humanized IgG1 antibody against HER2 is linked to the microtubule-disrupting agent MMAE. After binding HER2 on tumor cells and internalization, the released MMAE inhibits microtubule polymerization, causing cell cycle arrest and apoptosis. It is studied in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RC48, RC48-ADC
Drug type
Antibody-drug conjugate
Targets
HER2 (ERBB2) (ERBB2), tubulin (secondary target)
Mechanism
Kills target cells, directed at HER2 (ERBB2) (ERBB2)
Pathways
microtubule polymerization inhibition, G2/M cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
RemeGen Co., Ltd.
In trials of
PFE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
RB3U3A1S27

Conditions studied

Breast CancerBreast Neoplasms

Other drugs acting on ERBB2

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.